

The Promise of the Dual Prevention Pill

Barbara Friedland
Population Council

 bfriedland@popcouncil.org

HIV Prevention Technologies in Pipeline and Close to Introduction
NURHT Caucus
10 May 2022




The **Population Council** conducts biomedical, social science, and public health research. We deliver solutions that lead to more effective policies, programs, and technologies that improve lives around the world.

Women want multi-purpose technologies (MPTs)

- Women worldwide face dual risks of unintended pregnancy and HIV
- Risk of unintended pregnancy often outweighs concerns about HIV
- 83% of women prefer HIV/STI prevention products with contraception vs. HIV/STI prevention alone



Share your wisdom
Learn about women's health
Shape our future




Share.Learn.Shape.

An online women's health survey

Your answers can have a direct impact on new ways to prevent sexually transmitted diseases (STDs), including HIV.


Take the survey

 **POPULATION COUNCIL**
Ideas. Evidence. Impact.


Market Size Estimate for the DPP

In 15 countries in Sub-Saharan Africa:


- 251,000-1.25 million women per year might use DPP
- 5.4 million HIV-negative COC users (ages 15-49)



Considerations for the DPP and new biomedical technologies



DPP Acceptability Studies (2019-2023)



Perceived benefits of the DPP

- Empower women to access HIV and pregnancy prevention they can control themselves
 - Prevent school dropout in young women due to unplanned pregnancies
 - Protect against stealthing (removal of condom during sex without consent)
 - Provide protection during spontaneous sexual activity (condom access limited)
 - Offer protection in the event of rape
- Reduce frequency of clinic visits for women currently using both PrEP and COCs
- Lessen the burden of taking two separate pills
- Positively impact contraception and PrEP uptake

Source: n = 14 FGDs with age 16-40 from South Africa and Zimbabwe

Source: n = 29 health care providers from South Africa and Zimbabwe

Potential challenges for DPP

Product

- Side effects (double the side effects?)
- Daily dosing
- Duration of use

Service delivery

- Provider attitudes
- Waiting period/testing requirements
- Provision outside the facility
- Counseling tools to encourage informed choice
- Counseling for effective use
- Cost/ability to afford DPP

Social

- Partner approval
- Family and community leaders unsupportive of PrEP and/or COC use
 - Myths and misconceptions around COCs
 - HIV-related stigma
- Sociocultural norms and taboos regarding adolescent sexual behavior

Source: n = 14 FGDs with age 16–40 from South Africa and Zimbabwe

Source: n = 29 health care providers from South Africa and Zimbabwe

Summary

- DPP potentially the fastest MPT to market
- May overcome uptake and adherence barriers of oral PrEP
- Potential to expand contraceptive choice
- Key to assess integration and implementation challenges early in the product development lifecycle

Next steps

- Crossover clinical trials of over-encapsulated DPP poised to begin
- Protocol for larger study with co-formulated tablet in development

Acknowledgements

Study Participants

Population Council, DPP Acceptability

study team: Barbara Friedland, Sanyukta Mathur, Irene Bruce, Lorna Begg, Marlana Plagianos, Rebecca Brodsky, Bruce Variano, Loreley Villamide-Herrera, Susanna Grecky, Dan Loeven, Thierry Bonnaire, Brady Zieman, Lisa Haddad, Brooke Snyder

Wits RHI, Johannesburg, South Africa:

Thesla Palanee Phillips, Krishnaveni Reddy, Lebogang Maila, Onthatile Maboja, Lydia Mampuru, Siyanda Tenza, & Wits RHI team

UZ-CTRC, Harare, Zimbabwe:

Nyaradzo Mgodzi, Petina Musara, Adlight Dandadzi, Prisca Mutero, Lucy Godo, Terrance Kufakunesu, Natasha Sedze, Caroline Murombedzi, & Zengeza CRS team

Funding support for the DPP studies from



This presentation is made possible by the generous support of the American people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and U.S. Agency for International Development (USAID). The contents are the responsibility of the authors and do not necessarily reflect the views of PEPFAR, USAID, or the U.S. Government.

Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R34MH119982. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

© 2021 The Population Council. All rights reserved.

Use of these materials is permitted only for noncommercial purposes.

The following full source citation must be included:

Friedland, Barbara. 2022. “The Promise of the Dual Prevention Pill,” presented at virtual webinar, “HIV Prevention Technologies in Pipeline and Close to Introduction,” NURHT Caucus, 10 May 2022

This presentation may contain materials owned by others. User is responsible for obtaining permissions for use from third parties as needed.